Cassava Sciences Announces Positive Data with SavaDx from a Randomized Controlled Phase 2b Study of Simufilam
July 26, 2021 08:30 ET
|
Cassava Sciences, Inc.
SavaDx Detected Significant Changes in Plasma Levels of Altered Filamin A in Patients with Alzheimer’s Disease Before and After Simufilam TreatmentSimufilam 100 mg and 50 mg Reduced Plasma Levels of...
Cassava Sciences to Present New Clinical Dataset at 2021 Alzheimer’s Association International Conference
July 21, 2021 08:30 ET
|
Cassava Sciences, Inc.
- On Monday, July 26th, New Clinical Data for SavaDx to be Shared ina Poster Presentation - - On Thursday, July 29th, New Clinical Data for Simufilam to be Featured in a Podium Presentation - ...
Cassava Sciences Selects Clinical Research Organization for Phase 3 Clinical Program in Alzheimer’s Disease
June 21, 2021 16:10 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, June 21, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced the selection of Premier Research...
Cassava Sciences Provides Mid-Year Corporate Update, Clinical Development Progress and Announces Guidance on Clinical Data Release
June 21, 2021 08:30 ET
|
Cassava Sciences, Inc.
Open-label Study Completes Patient EnrollmentCognition Maintenance Study Initiated May 2020, now 30% Enrolled6-month Biomarker Data to be Presented at AAIC Conference in July9-month Safety &...
Cassava Sciences to Present at the Raymond James 2021 Human Health Innovation Conference
June 17, 2021 16:01 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, June 17, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been...
Cassava Sciences Announces the Appointment of Richard J. Barry to its Board of Directors
June 14, 2021 08:30 ET
|
Cassava Sciences, Inc.
- Mr. Barry To Contribute Additional Board-level Perspective Around Growth, Governance, Sustainability and Societal Goals – AUSTIN, Texas, June 14, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc....
Cassava Sciences to Participate in Q&A Panel Discussion on Alzheimer’s Disease
May 24, 2021 08:30 ET
|
Cassava Sciences, Inc.
- Virtual Panel to be Held on Wednesday, May 26th, 11:00am Eastern Time - - Discussion to be Moderated by Jason McCarthy, PhD, Head of Biotechnology Research at Maxim Group - AUSTIN, Texas, May 24,...
Cassava Sciences Announces New $2.7 Million Research Grant Award from National Institutes of Health
May 12, 2021 07:30 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, May 12, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been awarded...
Cassava Sciences Announces Initiation of Cognition Maintenance Study in Alzheimer’s disease
May 10, 2021 08:30 ET
|
Cassava Sciences, Inc.
- Randomized, Controlled Study is Designed to Evaluate Cognition in Patients Who Continue Versus Discontinue Simufilam Over Six Months – - Target Enrollment is 100 Study Participants - AUSTIN,...
Cassava Sciences Invited to Participate in B. Riley Securities’ Neuroscience Conference
April 27, 2021 08:30 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, April 27, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been...